Sarcopenia Assessment Techniques
Dharani Guttikonda, Amber L. Smith – 26 October 2021
An Update on the Management of Esophageal Variceal Hemorrhage
Hassaan A. Zia, Elizabeth S. Aby, Atoosa Rabiee – 26 October 2021
Live Vaccines in Pediatric Liver Transplant Recipients: “To Give or Not to Give”
Sarah Kemme, Taisa J. Kohut, Julia M. Boster, Tamir Diamond, Elizabeth B. Rand, Amy G. Feldman – 26 October 2021
Perceptions of Exercise and Its Challenges in Patients With Nonalcoholic Fatty Liver Disease: A Survey‐Based Study
Oliver Glass, Daniel Liu, Elizabeth Bechard, Cynthia D. Guy, Jane Pendergast, Anna Mae Diehl, Manal F. Abdelmalek – 25 October 2021 – Exercise is a foundational treatment for nonalcoholic fatty liver disease (NAFLD); however, the majority of patients are unable to initiate and maintain effective exercise habits and remain at increased risk for progressive liver disease. Barriers and limitations to exercise in patients with NAFLD have not been fully identified.
Prevalence of High Liver Stiffness and a Screening Strategy Using the SODA‐2B Score Among US Adults
Sebastian Niezen, Elliot B. Tapper, Hirsh Trivedi, Michelle Lai, Michael P. Curry, Kenneth J. Mukamal, Z. Gordon Jiang – 24 October 2021 – Cirrhosis, a rising cause of death in the United States, has an extended preclinical phase characterized by progressive liver fibrosis. Despite the developments in noninvasive fibrosis measurement, there is no recommended screening, in part due to an incomplete understanding of the disease epidemiology on a national scale. Herein, we aim to define the prevalence of liver fibrosis and compare strategies to identify the at‐risk population.
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1
Qiaofeng Qian, Yang Li, Jiajun Fu, Dewen Leng, Zhe Dong, Jiajun Shi, Hongjie Shi, Dengwei Cao, Xu Cheng, Yufeng Hu, Qiujie Luo, Manli Hu, Yong Ran, Hao Tang, Hui Liu, Jinping Liu – 23 October 2021
Programmed death 1 expressing CD8+CXCR5+ follicular T cells constitute effector rather than exhaustive phenotype in patients with chronic hepatitis B
Arshi Khanam, Lydia S. Y. Tang, Shyam Kottilil – 23 October 2021
In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model
Eléanor Luce, Clara Steichen, Mickaël Allouche, Antonietta Messina, Jean‐Marie Heslan, Thierry Lambert, Anne Weber, Tuan Huy Nguyen, Olivier Christophe, Anne Dubart‐Kupperschmitt – 22 October 2021
Shear stress–induced cellular senescence blunts liver regeneration through Notch–sirtuin 1–P21/P16 axis
Juan‐Li Duan, Bai Ruan, Ping Song, Zhi‐Qiang Fang, Zhen‐Sheng Yue, Jing‐Jing Liu, Guo‐Rui Dou, Hua Han, Lin Wang – 22 October 2021
Impact of Nuclear Factor Erythroid 2–Related Factor 2 in Hepatocellular Carcinoma: Cancer Metabolism and Immune Status
Norifumi Iseda, Shinji Itoh, Tomoharu Yoshizumi, Takahiro Tomiyama, Akinari Morinaga, Kyohei Yugawa, Masahiro Shimokawa, Tomonari Shimagaki, Huanlin Wang, Takeshi Kurihara, Yoshiyuki Kitamura, Yoshihiro Nagao, Takeo Toshima, Noboru Harada, Kenichi Kohashi, Shingo Baba, Kousei Ishigami, Yoshinao Oda, Masaki Mori – 22 October 2021 – We examined phosphorylated nuclear factor erythroid 2–related factor 2 (P‐NRF2) expression in surgically resected primary hepatocellular carcinoma (HCC) and investigated the association of P‐NRF2 expression with clinicopathological features and patient outcome.